Matrix Private Capital Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Matrix Private Capital Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,800	Closed	-$291K	–	273
2021 Q3	$291K	Sell	7,800 -100	-1%	-$3.48K	0.15%	130
2021 Q2	$322K	Sell	7,900 -2,200	-22%	-$81.3K	0.18%	118
2021 Q1	$343K	Sell	10,100 -1,200	-11%	-$41.6K	0.21%	110
2020 Q4	$359K	Sell	11,300 -500	-4%	-$13.1K	0.26%	96
2020 Q3	$303K	Sell	11,800 -1,700	-13%	-$38.8K	0.31%	86
2020 Q2	$347K	Buy	13,500 +1,500	+13%	+$30.4K	0.38%	78
2020 Q1	$184K	Buy	+12,000	New	+$261K	0.26%	100

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Matrix Private Capital Group's ITCI Position: Q4 2021 in Review

Matrix Private Capital Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2021, closing a stake of 7,800 shares — an estimated $291K sold.

Matrix Private Capital Group first reported a position in ITCI in Q1 2020 and held it in 7 quarters. The position peaked at $359K in Q4 2020. 208 funds tracked by Wall St. Rank hold ITCI as of Q4 2021.

Matrix Private Capital Group reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2021 after selling out during the quarter.
Matrix Private Capital Group sold 7,800 Intra-Cellular Therapies Inc. shares in Q4 2021, an estimated $291K.
Matrix Private Capital Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 7 quarters.
Matrix Private Capital Group's Intra-Cellular Therapies Inc. position peaked at $359K in Q4 2020.
208 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2021.

Based on Matrix Private Capital Group's 13F filing for Q4 2021, filed 14 Feb 2022.